Penumbra (PEN) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $301 million, up 11.1% year-over-year, driven by 21.2% U.S. thrombectomy growth and strong VTE franchise performance.

• Net income for Q3 2024 was $29.5 million, with diluted EPS of $0.75 and adjusted EBITDA of $56.7 million.

• Gross margin expanded to 66.5%, up from 65.6% in Q3 2023, with non-GAAP operating income of $40.3 million.

• The company exited its Immersive Healthcare business, incurring a $110.3 million impairment and restructuring charge, and realized $6 million in GAAP operating expense savings in Q3.

• A $200 million share repurchase program was authorized, with $100.4 million executed in Q3 2024.

Financial highlights

• U.S. sales comprised 75.2% of total revenue, with international at 24.8%; U.S. revenue increased 16.2% year-over-year, while international revenue declined 1.9%.

• Global thrombectomy revenue was $204.1 million, up 14% year-over-year; embolization and access business revenue was $96.9 million, up 5.5%.

• Non-GAAP operating expenses were $160 million (53.1% of revenue), with R&D at $25.2 million and SG&A at $139.7 million.

• Adjusted EBITDA margin was 18.8% for Q3 2024.

• Ended Q3 with $280.5 million in cash and cash equivalents, and no significant debt.

Outlook and guidance

• 2024 total revenue guidance reiterated at $1,180–$1,200 million, with expectations centered at the midpoint.

• Raised lower end of 2024 U.S. thrombectomy growth guidance to 24%-25%.

• Gross margin expansion of 100 to 150 basis points and non-GAAP operating margin expansion of 100 to 200 basis points expected for 2024, excluding Immersive Healthcare impairments.

• Annualized R&D and SG&A savings of $17 million and $23 million, respectively, expected following the Immersive Healthcare exit.

• Liquidity is considered sufficient for at least the next 12 months.